Cardiopulmonary Medicine  |   December 2020
Readmission Risk Factors and Heart Failure With Preserved Ejection Fraction
Author Notes
  • From the Department of Cardiovascular Medicine at Ascension Macomb-Oakland Hospital in Warren, Michigan. 
  • Financial Disclosures: None reported. 
  • Support: None reported. 
  •  *Address correspondence to Dustin Harmon, DO, Department of Cardiovascular Medicine, Ascension Macomb-Oakland Hospital, 12000 E. 12 Mile Road, Warren, MI, 48093-3570. Email:
Article Information
Cardiopulmonary Medicine   |   December 2020
Readmission Risk Factors and Heart Failure With Preserved Ejection Fraction
The Journal of the American Osteopathic Association, December 2020, Vol. 120, 831-838. doi:
The Journal of the American Osteopathic Association, December 2020, Vol. 120, 831-838. doi:

Context: Cases of heart failure with preserved ejection fraction (HFpEF) exacerbations continue to affect patients' quality of life and cause significant financial burden on our healthcare system.

Objective: To identify risk factors for readmission in patients discharged with a diagnosis of HFpEF.

Methods: Electronic health records of patients over 18 years of age with a primary diagnosis of HFpEF treated between August 1, 2017 and March 1, 2018 in a community hospital were retrospectively reviewed. The study population included patients with HFpEF greater than 40% who were screened but did not qualify for the ongoing CONNECT- HF trial being conducted by Duke Clinical Research. To be included, subjects had to fall into 1 of 2 classifications (NYHA Class II-IV or ACC/AHA Stage B-D) and have a life expectancy greater than 6 months. Patients were excluded if they had terminal illness other than HF, a prior heart transplant or were on a transplant list, a current or planned placement of a left ventricular assist device, chronic kidney disease requiring hemodialysis, inability to use mobile applications, or inability to participate in longitudinal follow up. Readmission rate was analyzed at 30 and 90 days along with patients’ demographics and associated comorbidities, including peripheral vascular disease, anemia, pulmonary hypertension, arrythmia, and valvular heart disease. Patients were risk stratified using the LACE index readmission score and the Charlson comorbidity index.

Results: Of the 492 cases of HFpEF identified during the 7-month study period, 212 patients were included. The majority of patients were women (126; 59.4%), had a median body mass index above 30 kg/m2 (123; 58%), and had pulmonary hypertension (94; 44.3%), anemia (146; 68.8%), and arrhythmia (101, 47.6%). Forty-five (21.2%) patients were readmitted for HFpEF within 90 days of initial discharge; 32 of those (71.1%) were readmitted within 30 days of initial discharge. Patients with higher LACE and Charlson comorbidity index scores were more likely to be readmitted within 90 days. Peripheral vascular disease (P=.002), tricuspid regurgitation (P=.001), pulmonary hypertension (P=.049), and anemia (P=.029) were risk factors associated with readmissions. Use of ACEi/ARBs (P=.017) was associated with fewer readmissions.

Conclusion: Anemia, peripheral vascular disease, pulmonary hypertension, and valvular heart disease are not only postulated mechanisms of HFpEF, but also important risk factors for readmission. These study findings affirm the need for continued research of the pathophysiology and associated comorbidities of the HFpEF population to improve quality of life and lower healthcare costs.

Subscribe to view more

For full access to this article, log in to an existing user account, purchase an annual subscription, or purchase a short-term subscription.

Order a subscription


Pay Per View

Entire Journal
30-Day Access


Buy Now

This Issue
7-Day Access


Buy Now

This article
24-Hour Access


Buy Now

Sign In Or Create an account

Please sign in using your login.
If you do not have an AOA login, you may create a new account.

Or Subscribe